COMMUNIQUÉS West-GlobeNewswire

Replimune Reports Fiscal Third Quarter 2024 Financial Results and Provides Corporate Update
08/02/2024
Positive data update in December 2023 for all 140 patients in the IGNYTE clinical trial cohort of RP1 in anti-PD1 failed melanoma demonstrating durability of response Centrally reviewed 12-month primary analysis data [...]
Health Catalyst to Announce Fourth Quarter and Full Year 2023 Operating Results and Host Conference Call on Thursday, February 22, 2024
08/02/2024
SALT LAKE CITY, Feb. 08, 2024 (GLOBE NEWSWIRE) -- Health Catalyst, Inc. ("Health Catalyst", Nasdaq: HCAT), a leading provider of data and analytics technology and services to healthcare organizations, will release its [...]
Neurona Therapeutics Raises $120M to Advance Groundbreaking Pipeline of Regenerative Cell Therapy Candidates for Chronic Neurological Disorders
08/02/2024
The financing, co-led by Viking Global Investors and Cormorant Asset Management with participation from The Column Group along with additional new and existing investors, follows promising early clinical data from NRTX- [...]
Tenaya Therapeutics Announces Pricing of Underwritten Offering
08/02/2024
SOUTH SAN FRANCISCO, Calif., Feb. 08, 2024 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (Nasdaq: TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver potentially curative [...]
The UK National Institute for Health and Care Excellence (NICE) Issues Final Draft Guidance to Provide Patients with a Natural Lens (Phakic Eye) Being Treated for Chronic Diabetic Macular Edema Access to ILUVIEN®
08/02/2024
NICE Final Draft Guidance recommends providing National Health System (NHS) patients with a phakic lens access to the only sustained-release treatment lasting up to 36 months for chronic diabetic macular edema (DME) [...]
Healthwise Ranked #1 in Patient Education in 2024 Best in KLAS Report
08/02/2024
BOISE, Idaho, Feb. 08, 2024 (GLOBE NEWSWIRE) -- Healthwise, a leader in evidence-based health education, technology, and services, has been ranked No. 1 in Patient Education by KLAS Research in the 2024 Best in KLAS [...]
Mineralys Therapeutics Announces $120 Million Private Placement Financing
08/02/2024
RADNOR, Pa., Feb. 08, 2024 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension, chronic kidney disease (“CKD [...]
Assembly Biosciences Announces Effective Date of Reverse Stock Split
08/02/2024
– Assembly Bio common stock expected to begin trading on a split-adjusted basis on February 12, 2024 – SOUTH SAN FRANCISCO, Calif., Feb. 08, 2024 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a [...]
Auron Selects First Development Candidate for its Portfolio of Next-Generation Targeted Cancer Treatments from its Novel AURIGIN™ Platform
08/02/2024
AUTX-703 has demonstrated potent growth inhibition in preclinical models of solid tumors and a hematological malignancy An overview of the Company’s AURIGIN platform to be presented at the American Association for [...]
Collegium to Report Fourth Quarter and Full-Year 2023 Financial Results on February 22, 2024
08/02/2024
STOUGHTON, Mass., Feb. 08, 2024 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a leading, diversified specialty pharmaceutical company committed to improving the lives of people living with serious [...]
Biora Therapeutics Announces Participation in Canaccord Genuity Inflammatory Bowel Disease Symposium
08/02/2024
SAN DIEGO, Feb. 08, 2024 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc . (Nasdaq: BIOR), the biotech company that is reimagining therapeutic delivery, today announced it will participate in the Inflammatory Bowel Disease [...]
Quoin Pharmaceuticals Files U.S. and International Patent Applications for Novel Netherton Syndrome Combination Product
08/02/2024
ASHBURN, Va., Feb. 08, 2024 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the “Company” or “Quoin”), a specialty pharmaceutical company exclusively focused on the development and commercialization of [...]
Madrigal Pharmaceuticals Announces Publication of the Phase 3 MAESTRO-NASH Trial of Resmetirom in the New England Journal of Medicine
08/02/2024
Resmetirom is the first investigational medicine for NASH to achieve fibrosis improvement and NASH resolution primary endpoints in a Phase 3 trial Detailed analyses reinforce the safety profile of resmetirom Resmetirom [...]
Sensus Healthcare Issued U.S. Patent for SRT-100 Vision® System (IG-SRT) Capabilities
08/02/2024
BOCA RATON, Fla., Feb. 08, 2024 (GLOBE NEWSWIRE) -- Sensus Healthcare, Inc. (Nasdaq: SRTS ), a medical device company specializing in highly effective, non-invasive, minimally-invasive and cost-effective treatments for [...]
InnovAge to Host Investor Day on February 27, 2024
08/02/2024
DENVER, Feb. 08, 2024 (GLOBE NEWSWIRE) -- InnovAge Holding Corp. (“InnovAge” or the “Company”) (Nasdaq: INNV), an industry leader in providing comprehensive healthcare programs to frail, and predominantly dual-eligible [...]
60 Degrees Pharmaceuticals Appoints Kristen Landon as Chief Commercial Officer
08/02/2024
To lead U.S. commercial relaunch of ARAKODA® (tafenoquine) for malaria prevention Will support Company plan to expand clinical research strategy in tick-borne diseases beyond acute babesiosis WASHINGTON, Feb. 08, 2024 ( [...]
Annual report 2023: ALK delivers 9% sales growth with profits up 50%
08/02/2024
08 February 2024 ALK’s ( ALKB:DC / OMX: ALK B / AKBLF ) Board of Directors has approved the company’s 2023 annual report. Following a robust performance in Q4, full-year results were in line with the latest outlook. ALK [...]
Optimi Announces Non-Brokered Private Placement
08/02/2024
VANCOUVER, British Columbia, Feb. 08, 2024 (GLOBE NEWSWIRE) -- Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FRA: 8BN) (“ Optimi ” or the “ Company ”), a Health Canada licensed drug researcher and formulator [...]
Amedisys Offers Molecular Testing for Rapid and Accurate Infection Diagnosis
08/02/2024
BATON ROUGE, La., Feb. 08, 2024 (GLOBE NEWSWIRE) -- Amedisys, Inc. (NASDAQ: AMED), a leading provider of home health, hospice and high-acuity care in the home, is now offering advanced molecular testing to its care [...]

Pages